Eli Lilly (LLY) shares are extending gains on Wednesday after the FDA approved Foundayo — the company’s first once-daily oral GLP-1 for chronic weight management. As investors cheered the pivot to a more convenient, non-injectable alternative for obesity treatment, LLY broke above its 20-day moving average (MA), indicating the upward momentum may sustain in the near-term.
Despite the headline rally, however, Eli Lilly stock remains down over 10% versus the start of 2026.
For LLY shares, Foundayo approval is a game-changer because the oral pill addresses two major hurdles in the GLP-1 market: administration and supply.
Unlike current leaders (Zepbound and Wegovy), which require weekly injections, Foundayo is a small-molecule pill that can be taken any time of day without food or water restrictions.
This real-world convenience is expected to significantly expand the patient pool, particularly for those hesitant about needles, helping the firm capture a larger slice of the multi-billion-dollar GLP-1 market over time.
Moreover, as a chemical-based pill rather than a complex biologic, Foundayo is easier and cheaper to manufacture at scale, potentially easing the chronic supply shortages that have plagued Lilly’s injectable portfolio.
According to Barchart, options pricing signals continued momentum ahead. The put-to-call ratio on contracts expiring mid-June sits at 0.5x currently, indicating a strong bullish skew.
Meanwhile, the upper price on those contracts suggests roughly 14% upside in Eli Lilly shares to $1,099 within the next three months.
This concentration of call-buying at higher strikes implies institutional smart money is positioning for a breakout toward the company’s all-time high.
It’s also worth mentioning that LLY also currently pays a dividend yield of 0.71%, which makes it all the more attractive as a long-term holding, at least for income-focused investors.
Wall Street analysts also seem to share options traders’ optimism on Eli Lilly, given the consensus rating on the pharmaceutical behemoth sits at “Strong Buy” currently.
